Intech Investment Management LLC Grows Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Intech Investment Management LLC lifted its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,092 shares of the company’s stock after purchasing an additional 24,318 shares during the period. Intech Investment Management LLC’s holdings in Hims & Hers Health were worth $1,985,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HIMS. Yong Rong HK Asset Management Ltd purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth $41,104,000. Principal Financial Group Inc. lifted its position in Hims & Hers Health by 370.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,365,769 shares of the company’s stock valued at $33,024,000 after acquiring an additional 1,075,355 shares during the last quarter. Wellington Management Group LLP lifted its position in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Hims & Hers Health in the fourth quarter valued at $18,048,000. Finally, Bank of New York Mellon Corp lifted its position in Hims & Hers Health by 128.7% in the fourth quarter. Bank of New York Mellon Corp now owns 1,244,953 shares of the company’s stock valued at $30,103,000 after acquiring an additional 700,500 shares during the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Down 3.0 %

NYSE HIMS opened at $32.85 on Friday. The stock has a market capitalization of $7.30 billion, a P/E ratio of 74.67 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The firm has a 50-day moving average price of $39.02 and a 200 day moving average price of $28.55.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,287 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the completion of the transaction, the insider now directly owns 209,661 shares of the company’s stock, valued at approximately $7,193,468.91. This trade represents a 10.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Michael Chi sold 7,259 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the transaction, the insider now directly owns 193,601 shares of the company’s stock, valued at approximately $4,659,976.07. This trade represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,015,547 shares of company stock valued at $36,146,450. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HIMS shares. Canaccord Genuity Group boosted their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Truist Financial boosted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. Citigroup restated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Bank of America lifted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday. Finally, Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $37.31.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.